References

• Egecioglu, E., Engel, J.A., & Jerlhag, E. (2013). The glucagon-like peptide 1 analogue, exendin4, attenuates the rewarding value of psychostimulant drugs in mice. Addiction Biology, 18(4), 792–802. https://doi.org/10.1111/j.1369-1600.2011.00427.x
• Eng, J., Kleinman, W.A., Singh, L., Singh, G., & Raufman, J.P. (1992). Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Journal of Biological Chemistry, 267(11), 7402–7405. https://doi.org/10.1016/S0021- 9258(18)42867-1
• Fortin, S.M., Roitman, M.F., & Ongur, D. (2019). GLP-1 receptor stimulation reduces cocaine seeking and modulates mesolimbic dopamine. Neuropsychopharmacology, 44(11), 1953–1961. https://doi.org/10.1038/s41386-019-0444-1
• Fortin, S.M., et al. (2020). Activation of GLP-1 receptors in the laterodorsal tegmental nucleus decreases opioid seeking behavior in rodents. Neuropsychopharmacology, 45(3), 504–512. https://doi.org/10.1038/s41386-019-0541-1
• Hansen, H.H., et al. (2015). Liraglutide improves memory and increases hippocampal CA1 neuron numbers in a mouse model of Alzheimer’s disease. Journal of Alzheimer’s Disease, 46(3), 877–888. https://doi.org/10.3233/JAD-143025
• Harasta, A.E., et al. (2018). GLP-1 receptor activation in the nucleus accumbens decreases cocaine-seeking behavior in rodents. Addiction Biology, 23(1), 213–221. https://doi.org/10.1111/adb.12491
• Hernandez, N.S., Ige, K.Y., Mietlicki-Baase, E.G., et al. (2018). GLP-1 receptor activation in the ventral tegmental area reduces cocaine self-administration and associated dopamine release. Molecular Psychiatry, 23(5), 932–941. https://doi.org/10.1038/mp.2017.135
• Mietlicki-Baase, E.G., et al. (2017). A GLP-1 receptor agonist in the lateral dorsal tegmental nucleus suppresses food intake. Neuropharmacology, 113, 73–80 https://doi.org/10.1016/j.neuropharm.2016.09.012
• Penn State and Caron Treatment Centers. (Unpublished). Liraglutide in opioid use disorder: A pilot study in a residential treatment setting. Internal data on file. Study showed a 40% reduction in opioid craving among participants treated with liraglutide
• Pi-Sunyer, X., et al. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892
• Silverman, K., et al. (2023). Semaglutide for alcohol use disorder: A randomized clinical trial. JAMA Psychiatry, 80(9), 928–937. https://doi.org/10.1001/jamapsychiatry.2023.2336
• Shirazi, R.H., et al. (2013). Glucagon-like peptide-1 receptor activation decreases alcohol intake in rodents. Addiction Biology, 18(4), 676–688. https://doi.org/10.1111/adb.12012
• Tuesta, L.M., et al. (2017). GLP-1 receptor activation in the VTA and nucleus accumbens blocks nicotine reward. Journal of Neuroscience, 37(5), 1039–1047. https://doi.org/10.1523/JNEUROSCI.1565-16.2016
• Vallöf, D., et al. (2019). The GLP-1 analogue semaglutide attenuates alcohol drinking and relapse-like behavior in rodents. Neuropsychopharmacology, 44(7), 1212–1220. https://doi.org/10.1038/s41386-019-0340-8
• Wilding, J.P.H., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183